NEW YORK (GenomeWeb News) – BioMarker Strategies today announced it is being granted a $1.5 million Small Business Innovation Research Phase II award to further develop its companion diagnostic for melanoma.

The grant from the National Cancer Institute will go toward the Baltimore, Md.-based firm's refinement of its PathMap assay and ex vivo protocols developed under a Phase I SBIR contract. The new funding will also support validation of PathMap in human clinical samples, BioMarker Strategies said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Two researchers have found that behavioral genetic defenses in criminal cases don't tend to affect outcomes, according to Popular Science.

Researchers report that while host genetics influence the oral microbiome, they don't appear to affect cavity-causing microbes, the Economist says.

Pandas' gut microbiomes change as what they eat changes with the seasons, writes Discover's Inkfish blog.

In PLOS this week: comparative genomic study of malaria-linked macaque parasite, search for apple root reference genes, and more.